The Cmax was 466 μg/mL (20%), whereas the AUC0–21d was 4,120 μg/day/mL (21%) following administration to patients with advanced HER2 + BC and relapsed or refractory status, with a volume of distribution of 5.47 L (22%). Here, ERBB2 is linked to breast cancer.